CRP and COVID-19: A single-center study in COVID-19 patients admitted to the ICU (71 with vs. 79 without secondary infections) demonstrated that steroids and Tocilizumab, alone or combined, cause the suppression of PCT and CRP production, with a considerable decrease in the relationship between these biomarkers and secondary infections [26].